Lucid
2320 Brighton-Henrietta Townline Road
Rochester
New York
14623
United States
Tel: 585-239-9800
Fax: 585-239-9806
Website: http://www.lucid-tech.com/
Email: info@lucid-tech.com
24 articles about Lucid
-
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
11/13/2023
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2023.
-
Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry
12/8/2022
Lucid Diagnostics Inc. today announced that the Company was selected as one of ten finalists for the Medtech Company of the Year 2022.
-
Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research
12/1/2022
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck ® Cell Collection Device (“EsoCheck”) at the American Association for Cancer Research’s (“AACR”) Special Conference.
-
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
11/2/2022
Lucid Diagnostics Inc. today announced that the Company will host a business update conference call and webcast on Monday, November 14, 2022, at 4:30 PM EDT.
-
Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements
8/2/2022
Lucid Diagnostics Inc. today announced that LucidDx Labs Inc. (“LucidDx Labs”), has entered into participating provider agreements with preferred provider organizations Prime Healthcare, Three Rivers Provider Network, and Galaxy Health Network (the “PPOs”), as well as Alivio Health, a specialized diagnostic laboratory network.
-
Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer
10/21/2021
Lucid Diagnostics Inc. today announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.
-
Lucid Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
8/17/2012
-
Lucid’s Cellular Imaging Technology part of German Association of Scientific Medical Societies Dermatological Guidelines
3/19/2012
-
Lucid’s Cellular Imaging Technology to be Highlighted at Annual Meeting of the American Academy of Dermatology
3/14/2012
-
Lucid Announces Separation of Unit to Common Stock and Warrant
2/29/2012
-
Lucid Announces Closing of Public Offering
1/3/2012
-
Lucid Files IPO For Up To $28.8M To Repay Debt, Expand Business
4/19/2011
-
Lucid To Present at the Rodman & Renshaw Healthcare Conference on September 15
9/8/2010
-
Dermatologists and Pathologists to Begin Collaborating with Lucid's Proprietary VivaNet® System
2/18/2009
-
Lucid Receives FDA Clearance to Market Its VivaScope(R) Reflective Confocal Microscope System in the U.S.
9/30/2008
-
Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
3/25/2008
-
Lucid Expands Support Internationally: Dr. Colin Stahel Appointed Director for Asia Pacific Region
12/11/2007
-
William Shea Elected as Chairman of Lucid
12/3/2007
-
Lucid VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
10/16/2007
-
Lucid Release: Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9/18/2007